Tokyo-based Asklep joins Medidata partner programme to expand clinical trial services
Asklep has joined the Medidata Solutions Partner Programme to increase the quality and efficiency of clinical trials.
Asklep, a leading provider of clinical research services based in Tokyo, has announced its decision to join the Medidata Solutions Partner Programme.
The move is part of the company's strategy to expand its clinical trial services in the Asia Pacific region and support its sponsors more effectively.
It will use the Medidata platform to increase the quality and efficiency of its clinical trials and post-marketing studies, helping to streamline key areas of the clinical trials process for its customers.
By seeking several accreditations across Medidata's cloud-based platform, Asklep will benefit from being able to offer a variety of on-demand resources, including electronic data capture and clinical data management.
Masahito Ikeda, corporate officer and deputy division director of clinical information at the company, said: "It's critical that our partners share our mission and dedication to improving the clinical trial process for research sponsors.
"We've been impressed with Medidata's track record streamlining global trials of all sizes and phases and the strong preference among sites to use the Medidata platform for electronic patient data capture."
Tarek Sherif, chief executive officer of Medidata Solutions, added that Asklep joins a growing community of partners that use the company's cloud-based platform to improve productivity and reduce costs.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance